<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634604</url>
  </required_header>
  <id_info>
    <org_study_id>ROP3</org_study_id>
    <secondary_id>UG1EY011751</secondary_id>
    <nct_id>NCT04634604</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP</brief_title>
  <acronym>ROP3</acronym>
  <official_title>A Randomized Trial of Low-Dose Bevacizumab Versus Laser for Type 1 Retinopathy of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Eye Disease Investigator Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial will compare retinal outcomes with low-dose intravitreous&#xD;
      bevacizumab (0.063 mg) versus laser photocoagulation as treatment for infants with type 1&#xD;
      retinopathy of prematurity (ROP).&#xD;
&#xD;
      The study also will assess neurodevelopment, refractive error, visual acuity, and peripheral&#xD;
      visual fields.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infants with type 1 ROP and no prior treatment for ROP will be randomly assigned (1:1) to&#xD;
      treatment with either intravitreous bevacizumab 0.063 mg or peripheral retinal laser&#xD;
      ablation. Study exams will be at weeks 1, 2, and 4 weeks, and at 2 and 4-months&#xD;
      post-treatment (and re-treatment when indicated). Additional study exams will occur at&#xD;
      adjusted age 6 months, 1 year, and then annually for 5 more years. Non-study examinations&#xD;
      will be at clinician discretion and are likely to occur more often. The primary outcome will&#xD;
      be treatment success, defined as no worsening of ROP 5-13 days after treatment (or&#xD;
      re-treatment if indicated), no plus disease or severe neovascularization 2 weeks to 6 months&#xD;
      after treatment (or re-treatment if indicated), and no unfavorable structural outcome (or&#xD;
      prior scleral buckle or vitrectomy) at 6 months adjusted age. Important secondary outcomes&#xD;
      include the number of re-treatments, extent of retinal vascularization, refractive error,&#xD;
      neurodevelopment assessed by the Bayley-4 test, IQ and neuropsychiatric testing, visual&#xD;
      acuity, visual fields, and systemic morbidities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">April 2029</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success Rate At 6 Months Adjusted Age</measure>
    <time_frame>6 Months Adjusted Age</time_frame>
    <description>The primary objective for the randomized trial is to determine if infants with type 1 ROP treated with intravitreal bevacizumab (subsequently referred to as BV) have a treatment success rate determined at 6 months adjusted age that is non-inferior compared with infants treated with laser photocoagulation (subsequently referred to as LASER).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by Occupational Safety and Health Administration (OSHA) and facility standards, will be followed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>For infants randomized to bevacizumab, the Intravitreous bevacizumab 0.063 mg injection will be given no later than 2 days after the diagnosis of type 1 ROP. The ophthalmologist may choose to give the intravitreous injection in the operating room or at the bedside, with or without anesthesia, after consultation with the attending neonatologist. A binocular indirect ophthalmoscope with an appropriate condensing lens should be available, and the pupils should be dilated.</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser</intervention_name>
    <description>For infants randomized to laser treatment, it will be given in conjunction with a binocular indirect ophthalmoscope and an appropriate condensing lens, by a study-certified ophthalmologist experienced in the use of this equipment. The treating investigator will be certified as having sufficient experience with laser for ROP, and adequacy of laser treatment will be confirmed by expert review of photographs. Special laser precautions, as mandated by OSHA and facility standards, will be followed.</description>
    <arm_group_label>Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Birth weight &lt; 1251 grams&#xD;
&#xD;
          -  Newly diagnosed (within 2 days) type 1 ROP in one or both eyes; meeting the following&#xD;
             criteria:&#xD;
&#xD;
               -  Zone I, any stage ROP with plus disease, with retinal vessels or ROP in Zone II&#xD;
                  in any quadrant, or&#xD;
&#xD;
               -  Zone I, stage 3 ROP without plus disease, with retinal vessels or ROP in zone II&#xD;
                  in any quadrant or&#xD;
&#xD;
               -  Zone II, stage 2 or 3 ROP with plus disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment for ROP&#xD;
&#xD;
          -  Stage 4 or 5 ROP in either eye&#xD;
&#xD;
          -  All ROP in zone I in either eye (no retinal vessels or ROP extend into zone II in any&#xD;
             quadrant)&#xD;
&#xD;
          -  Either treatment could not be done within 2 days of diagnosis of type 1 ROP&#xD;
&#xD;
          -  Investigator unwilling to randomize or parent unwilling to accept random assignment to&#xD;
             either treatment&#xD;
&#xD;
          -  Transfer to another hospital not covered by study-certified examiners anticipated&#xD;
             within the next 4 weeks&#xD;
&#xD;
          -  Active ocular infection or purulent nasolacrimal duct obstruction in either eye&#xD;
&#xD;
        One eye will be excluded, and other eye may be eligible, if either of the following are&#xD;
        present:&#xD;
&#xD;
          -  Visually significant ocular anomaly (e.g., cataract, coloboma)&#xD;
&#xD;
          -  Opacity that precludes an adequate view of the retina&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David K Wallace, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raymond T Kraker, MSPH</last_name>
    <phone>8139758690</phone>
    <email>rkraker@jaeb.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brooke P Fimbel</last_name>
    <phone>813-975-8690</phone>
    <email>bfimbel@jaeb.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizonia Pediatric Eye Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L Plotnik, MD</last_name>
      <phone>480-513-6920</phone>
      <email>JPlotnik@phoenixchildrens.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arkansas Childrens Hospital/ University of Arkansas Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florin Grigorian, MD</last_name>
      <phone>501-364-4125</phone>
      <email>fgrigorian@uams.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ of California, Irvine- Gavin Herbert Eye Institute</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donny Suh, MD, MBA</last_name>
      <phone>949-824-9089</phone>
      <email>dowsuh@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela M Estrada, MD</last_name>
      <phone>916-734-8755</phone>
      <email>mmestrada@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Department of Ophthalmology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandra de Alba Campomanes, MD</last_name>
      <phone>415-353-2560</phone>
      <email>dealbaa@vision.ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren C Mehner, MD, MPH</last_name>
      <phone>720-848-2500</phone>
      <email>lauren.mehner@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Denver Health and Hospital Authority</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse M Smith, MD</last_name>
      <phone>303-436-6000</phone>
      <email>jesse.smith@dhha.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Connecticut Childrens Medical Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine E Collinge, MD</last_name>
      <phone>860-837-9600</phone>
      <email>jcollinge@connecticutchildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Hutchinson, MD</last_name>
      <phone>404-778-4725</phone>
      <email>amy.hutchinson@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hawke H Yoon, MD</last_name>
      <phone>312-227-6719</phone>
      <email>HYoon@luriechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U of Illinois at Chicago Eye and Ear Infirmary</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel E Maidana, MD, PhD</last_name>
      <email>maidana@uic.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Hyde Park</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah H Rodriguez</last_name>
      <phone>773-702-3937</phone>
      <email>srodriguez5@bad.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David K Wallace, MD, MPH</last_name>
      <phone>317-278-2651</phone>
      <email>dwallac@iu.edu</email>
    </contact>
    <investigator>
      <last_name>David K Wallace, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Haider, MD</last_name>
      <phone>317-274-1214</phone>
      <email>khaider@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UK Ophthalmology and Visual Sciences, The Eye Clinic</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John M Franklin, MD</last_name>
      <phone>859-323-5868</phone>
      <email>john.franklin@uky.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204-5809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison A Jensen, MD</last_name>
      <phone>443-849-6341</phone>
      <email>ajensen@gbmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Wu, MD</last_name>
      <email>carolyn.wu@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri- Columbia Mason Eye Institute</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed M Elkeeb, MD</last_name>
      <phone>573-875-9000</phone>
      <email>elkeeba@health.missouri.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis University Ophthalmology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradeley V Davitt, MD</last_name>
      <phone>314-977-4931</phone>
      <email>davittb@slu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samiksha Fouzdar Jain, MD</last_name>
      <phone>402-559-3480</phone>
      <email>sjain@childrensomaha.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian David H Koch Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Orlin, MD</last_name>
      <phone>646-697-6428</phone>
      <email>ano9028@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Go, MD</last_name>
      <phone>919-966-5296</phone>
      <email>michelle_go@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon F Freedman, MD</last_name>
      <phone>919-684-2038</phone>
      <email>Freed003@mc.duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Yang, MD</last_name>
      <phone>513-636-4751</phone>
      <email>Michael.Yang@cchmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Ophthalmology Associates, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine O Jordan, MD</last_name>
      <phone>614-224-6222</phone>
      <email>cateolsonjordan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Campbell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Eye Center of Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Nischal, MD</last_name>
      <phone>412-692-5918</phone>
      <email>nischalkk@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Storm Eye Institute</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Bowsher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital - Dept. Of Ophthalmology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Bhatt, MD</last_name>
      <phone>832-822-3230</phone>
      <email>arbhatt@texaschildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Woman's Hospital of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charity H Grannis, MD</last_name>
      <phone>713-790-1234</phone>
      <email>cgrannis@houstoneye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Elizabeth Hartnett, MD</last_name>
      <phone>801-581-2352</phone>
      <email>ME.Hartnett@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Pediatric Eye Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Crouch, MD</last_name>
      <phone>757-461-0050</phone>
      <email>ercrouch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johane M Robitaille, MD</last_name>
      <phone>902-470-8731</phone>
      <email>jrobitai@dal.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masrin Najm-Tehran, MD</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>201401</phone_ext>
      <email>nasrin.tehrani@sickkids.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU - Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosanne Superstein, MD</last_name>
      <phone>514-345-4715</phone>
      <email>rosanne.superstein@mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pedig.net</url>
    <description>PEDIG Public Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Yes In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the Pediatric Eye Disease Investigator Group (PEDIG) public website after the completion of each protocol and publication of the primary manuscript.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be made available after publication of each primary manuscript.</ipd_time_frame>
    <ipd_access_criteria>Users accessing the data must enter an email address.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 26, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04634604/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 5, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04634604/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 25, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04634604/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

